Alto IngredientsALTO
ALTO logo
Fair Value
US$9
Share price04 Jun
US$5.6737.0% undervalued intrinsic discount
Loading
1Y353.60%
7D1.98%

Domestic Tax Credit And Exports Will Unlock Renewable Potential

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
04 May 25
Updated
04 Jun 26
Views
214
Not Invested

Last Update 04 Jun 26

Fair value Increased 33%

ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside

Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups.

Analyst Commentary

Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus. While the datapoints relate to another issuer in the MASH and metabolic space, the themes help explain why Alto Ingredients' updated fair value embeds more conservative multiples alongside refreshed views on growth and execution risk.

Bullish Takeaways

  • Bullish analysts view fully funded or well-capitalized clinical programs as a clear positive for execution, which supports using revenue and earnings trajectories with fewer financing haircuts when assigning fair value to Alto Ingredients.
  • Where peers have narrowed focus to high conviction programs, analysts have been willing to assign value to additional indications once there is supporting data and a clearer clinical path. This reinforces the idea that Alto Ingredients could see incremental valuation credit as its own growth drivers and margin levers become more visible.
  • Some bullish analysts describe differentiated assets and thoughtful trial design as reasons to maintain constructive views despite share issuance. This suggests that investors may tolerate a lower P/E multiple if they see a credible route to scaling earnings and return on invested capital over time.
  • Analysts pointing to strong cash runways and aligned regulatory paths for peers highlight that balance sheet strength and clear milestones can help support Alto Ingredients' revised fair value, even with more cautious assumptions around valuation multiples.

Bearish Takeaways

  • Bearish analysts have trimmed price targets for peer companies after dilution events, showing that additional shares and funding needs can cap upside for Alto Ingredients if future capital raises are required to support expansion or working capital.
  • Target resets that cite lower valuation multiples, despite constructive views on long term programs, indicate that investors may be less willing to pay premium P/E levels for Alto Ingredients until there is clearer evidence on execution, margin durability, and capital intensity.
  • Research that flags recent share price pullbacks as overdone still acknowledges volatility around clinical and funding milestones, which can also affect sentiment for Alto Ingredients if results, volumes, or cost improvements arrive slower than expected.
  • The reliance on specific clinical readouts and regulatory events as catalysts in peer coverage underlines that Alto Ingredients' fair value is sensitive to timing and quality of operational milestones, and that any delays or weaker outcomes could justify further multiple compression.

What's in the News

  • From October 1, 2025 to December 31, 2025, Alto Ingredients did not repurchase any shares under its existing buyback program. A total of 0 shares were repurchased for US$0 million during this period. (Source: Key Developments)
  • The company has completed the repurchase of 2,552,377 shares, representing 3.37% of its shares, for a total of US$6.04 million under the buyback originally announced on September 12, 2022. (Source: Key Developments)
  • Broader ethanol market attention continues around US gasoline policy, with reports that the White House is preparing an E15 waiver for summer gasoline sales. This item references the fuel market generally and not Alto Ingredients specifically, but it can shape how investors think about ethanol producers. (Source: Bloomberg via periodicals)

Valuation Changes

  • Fair Value: The updated fair value estimate has risen from $6.75 to $9.00 per share, a change of roughly 33%.
  • Discount Rate: The discount rate has edged down from 7.72% to 7.58%, indicating a slightly lower required return in the model.
  • Revenue Growth: The assumed long term revenue growth has moved from 2.47% to 3.24%, reflecting a higher top line growth input.
  • Net Profit Margin: The modeled net profit margin has increased from 4.18% to 6.29%, implying a higher expected earnings contribution for each dollar of revenue.
  • Future P/E: The future P/E multiple has been reduced from 15.7x to 13.6x, indicating a more conservative valuation multiple in the forecast.
19 viewsusers have viewed this narrative update

Key Takeaways

  • Tax credit extensions and regulatory shifts favor Alto, enhancing profitability, market positioning, and supporting revenue and margin growth through renewable fuels and premium exports.
  • Strategic acquisitions, operational improvements, and sustained cost-efficiency measures are strengthening margins, earnings quality, and enabling scalable growth in higher-value, lower-carbon products.
  • Heavy reliance on volatile ethanol markets, policy incentives, and outdated technology exposes the company to earnings instability, competitive pressures, and long-term demand erosion risks.

Catalysts

About Alto Ingredients
    Produces, distributes, and markets specialty alcohols, renewable fuel, and essential ingredients in the United States.
What are the underlying business or industry changes driving this perspective?
  • The extension and expansion of the 45Z federal tax credit for domestic renewable fuels through 2029, combined with Alto's ongoing initiatives to lower carbon intensity at its plants, is expected to significantly enhance profitability and cash flows over the next several years-estimated to provide at least $18 million in incremental earnings opportunity across two major facilities by 2026, boosting both net margins and intrinsic asset value.
  • Increasing regulatory focus on supporting U.S. grown feedstock and higher ethanol blend requirements, as well as tightening eligibility criteria for credits (favoring domestic producers), positions Alto Ingredients to benefit from a growing global and domestic market for renewable fuels, supporting future revenue growth.
  • Alto's successful expansion into the European ISCC export market for higher-margin, high-quality alcohols is already driving incremental revenue, while capacity for further growth remains-and strategic investments to repair infrastructure (like the dock) will enable sustained growth in premium exports, supporting both revenue and margin improvement.
  • The Carbonic acquisition and operational improvements at key plants have led to markedly higher CO2 production and utilization, with synergies and further upside yet to be realized; continued optimization is expected to drive additional gross profit and increase overall EBITDA sustainability.
  • Ongoing overhead reduction initiatives and cost-efficiency measures, which are exceeding annualized savings targets, will continue to lower SG&A and COGS, providing lasting improvement in operating leverage and thus enhancing earnings quality and scalability as Alto realigns toward higher-value, lower-carbon product lines.
Alto Ingredients Earnings and Revenue Growth

Alto Ingredients Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Alto Ingredients's revenue will grow by 3.2% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 3.1% today to 6.3% in 3 years time.
  • Analysts expect earnings to reach $63.5 million (and earnings per share of $0.78) by about June 2029, up from $28.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $94.6 million in earnings, and the most bearish expecting $44.5 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.7x on those 2029 earnings, down from 15.3x today. This future PE is lower than the current PE for the US Chemicals industry at 28.0x.
  • Analysts expect the number of shares outstanding to grow by 0.11% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.58%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistent operational volatility, evidenced by recurring losses (Q2 2025 net loss of $11.3 million versus $3.4 million in Q2 2024) and negative adjusted EBITDA, exposes Alto Ingredients to risks of structurally low earnings and limited capacity to deliver sustainable net margin improvement in a highly competitive industry.
  • Continued overreliance on commodity fuel ethanol sales (with fewer gallons sold at lower prices in Q2 2025), alongside high sensitivity to crush margins and derivative swings, suggests ongoing exposure to the secular trend of declining internal combustion engine demand and transportation electrification, threatening long-term core revenue streams.
  • The company's dependence on governmental incentives-especially 45Z credits expiring in 2029 and regulations that may shift toward non-corn-based or next-generation biofuels-presents vulnerability to policy change or erosion of support for conventional corn ethanol, which could negatively impact both revenue and earnings predictability.
  • Intensifying competition in the specialty alcohol and ingredients market (noted by falling high-value alcohol premiums and margin compression in Q2), along with limited historical investment in proprietary technology or brand differentiation, risks Alto's ability to offset declining margins in its traditional segments, thereby constraining future top-line growth.
  • Input cost volatility, particularly with rising commodity reference prices for corn and soybeans and uncertainty surrounding sustainable low-carbon feedstock sourcing, could lead to higher cost of goods sold and margin contraction-especially if climate impacts further tighten supply-pressuring gross and net margins longer-term.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $9.0 for Alto Ingredients based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $8.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.0 billion, earnings will come to $63.5 million, and it would be trading on a PE ratio of 13.7x, assuming you use a discount rate of 7.6%.
  • Given the current share price of $5.53, the analyst price target of $9.0 is 38.6% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Alto Ingredients?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$9
vs US$5.6737.0% undervalued intrinsic discount
PastFuture-80m2b2015201820212024202620272029Revenue US$1.0bEarnings US$63.5m
3.2%
Revenue growth
6.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Alto Ingredients

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with excellent balance sheet.

Market capUS$451.7m
PB1.8x
Estimated Growth2.7%
Dividend YieldN/A
Full analysis

CEO & management

Bryon McGregor
CEO
2.9yrs
CEO Tenure

Produces, distributes, and markets specialty alcohols, renewable fuel, and essential ingredients in the United States.